Helicobacter pylori infection exacerbates metabolic dysfunction-associated steatotic liver disease through lipid metabolic pathways: a transcriptomic study

被引:0
|
作者
Chen, Xingcen [1 ,2 ,3 ]
Peng, Ruyi [1 ,2 ,3 ]
Peng, Dongzi [1 ,2 ,3 ]
Liu, Deliang [1 ,2 ,3 ]
Li, Rong [1 ,2 ,3 ]
机构
[1] Cent South Univ, Xiangya Hosp 2, Dept Gastroenterol, 139 Middle Renmin Rd, Changsha 410011, Hunan Prov, Peoples R China
[2] Cent South Univ, Res Ctr Digest Dis, 139 Middle Renmin Rd, Changsha 410011, Hunan Prov, Peoples R China
[3] Clin Res Ctr Digest Dis Hunan Prov, Changsha 410011, Hunan Prov, Peoples R China
基金
中国国家自然科学基金;
关键词
Helicobacter pylori; Metabolic dysfunction-associated steatotic liver disease; Transcriptome sequencing; FABP5; PPAR signaling pathway; ACID; PATHOGENESIS; RESISTANCE;
D O I
10.1186/s12967-024-05506-y
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background The relationship between Helicobacter pylori (H. pylori) infection and metabolic dysfunction-associated steatotic liver disease (MASLD) has attracted increased clinical attention. However, most of those current studies involve cross-sectional studies and meta-analyses, and experimental mechanistic exploration still needs to be improved. This study aimed to investigate the mechanisms by which H. pylori impacts MASLD. Methods We established two H. pylori-infected (Cag A positive and Cag A negative) mouse models with 16 weeks of chow diet (CD) or high-fat diet (HFD) feeding. Body weight, liver triglyceride, blood glucose, serum biochemical parameters, inflammatory factors, and insulin resistance were measured, and histological analysis of liver tissues was performed. Mouse livers were subjected to transcriptome RNA sequencing analysis. Results Although H. pylori infection could not significantly affect serum inflammatory factor levels and serum biochemical parameters in mice, serum insulin and homeostatic model assessment for insulin resistance levels increased in CD mode. In contrast, H. pylori Cag A + infection significantly aggravated hepatic pathological steatosis induced by HFD and elevated serum inflammatory factors and lipid metabolism parameters. Hepatic transcriptomic analysis in the CD groups revealed 767 differentially expressed genes (DEGs) in the H. pylori Cag A + infected group and 1473 DEGs in the H. pylori Cag A- infected group, and the "nonalcoholic fatty liver disease" pathway was significantly enriched in KEGG analysis. There were 578 DEGs in H. pylori Cag A + infection combined with the HFD feeding group and 820 DEGs in the H. pylori Cag A- infected group. DEGs in the HFD groups were significantly enriched in "fatty acid degradation" and "PPAR pathway." Exploring the effect of different Cag A statuses on mouse liver revealed that fatty acid binding protein 5 was differentially expressed in Cag A- H. pylori. DEG enrichment pathways were concentrated in the "PPAR pathway" and "fatty acid degradation." Conclusions Clinicians are expected to comprehend the impact of H. pylori on MASLD and better understand and manage MASLD. H. pylori infection may exacerbate the development of MASLD by regulating hepatic lipid metabolism, and the H. pylori virulence factor Cag A plays a vital role in this regulation.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Metabolic dysfunction-associated steatotic liver disease and the heart
    Driessen, Stan
    Francque, Sven M.
    Anker, Stefan D.
    Cabezas, Manuel Castro
    Grobbee, Diederick E.
    Tushuizen, Maarten E.
    Holleboom, Adriaan G.
    [J]. HEPATOLOGY, 2023,
  • [2] Menopause and metabolic dysfunction-associated steatotic liver disease
    Polyzos, Stergios A.
    Goulis, Dimitrios G.
    [J]. MATURITAS, 2024, 186
  • [3] Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
    Castillo-Nunez, Yulino
    Almeda-Valdes, Paloma
    Gonzalez-Galvez, Guillermo
    Arechavaleta-Granell, Maria del Rosario
    [J]. CURRENT DIABETES REPORTS, 2024, 24 (07) : 158 - 166
  • [4] Metabolic profiling of tryptophan pathways: Implications for obesity and metabolic dysfunction-associated steatotic liver disease
    Arto, Carmen
    Rusu, Elena Cristina
    Clavero-Mestres, Helena
    Barrientos-Riosalido, Andrea
    Bertran, Laia
    Mahmoudian, Razieh
    Aguilar, Carmen
    Riesco, David
    Chicote, Javier Ugarte
    Parada, David
    Martinez, Salome
    Sabench, Fatima
    Richart, Cristobal
    Auguet, Teresa
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2024,
  • [5] Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis
    Mantovani, Alessandro
    Lando, Maria Giovanna
    Borella, Nicolo
    Scoccia, Enrico
    Pecoraro, Barbara
    Gobbi, Federico
    Bisoffi, Zeno
    Valenti, Luca
    Tilg, Herbert
    Byrne, Christopher D.
    Targher, Giovanni
    [J]. LIVER INTERNATIONAL, 2024, 44 (07) : 1513 - 1525
  • [6] From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
    Chen, Li
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2023, 15 (12) : 1253 - 1257
  • [7] Nutrients associated with metabolic dysfunction-associated steatotic liver disease
    Jeong, Seogsong
    [J]. JOURNAL OF HEPATOLOGY, 2024, 80 (02) : e81 - e82
  • [8] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
    Eskridge, Wayne
    Cryer, Donna R.
    Schattenberg, Joern M.
    Gastaldelli, Amalia
    Malhi, Harmeet
    Allen, Alina M.
    Noureddin, Mazen
    Sanyal, Arun J.
    [J]. JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [9] The interplay between Helicobacter pylori infection and rs738409 PNPLA3 in metabolic dysfunction-associated steatotic liver disease
    Maiorana, Facundo
    Neschuk, Magali
    Caronia, Maria Virginia
    Elizondo, Karina
    Robledo, Maria Laura
    Schneider, Adolfo
    Veron, Georgina
    Zapata, Pedro Dario
    Barreyro, Fernando Javier
    [J]. PLOS ONE, 2024, 19 (09):
  • [10] Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease
    Long, Qichen
    Luo, Fengming
    Li, Binghui
    Li, Ziyang
    Guo, Zhe
    Chen, Zhiyang
    Wu, Weimin
    Hu, Min
    [J]. HEPATOLOGY COMMUNICATIONS, 2024, 8 (03)